Our study provides a scientific rational to illustrate the mechanism of drug resistance of SCLC to recombinant human arginase, and targeting Akt/mTOR/ASS1 axis might be an encouraging option in future clinical practice. The gene discussed is AKT1; the disease is small cell lung carcinoma.